Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2026)

Amylyx Pharmaceuticals' Enterprise Value history runs 6 years deep, the most recent figure standing at -$279.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 37.1% year-over-year to -$279.8 million in Q1 2026; TTM through Mar 2026 was -$279.8 million, a 37.1% decrease from a year earlier, with the FY2025 full-year figure at -$317.0 million, down 79.59% from the prior year.
• Enterprise Value improved to -$279.8 million in Q1 2026 per AMLX's latest filing, from -$317.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$162.6 million in Q3 2022 and bottomed at -$373.3 million in Q1 2024.
• The 5-year median for Enterprise Value is -$309.8 million (2024), against an average of -$283.6 million.
• Across the five-year window, Enterprise Value tumbled 260.96% in 2022 and jumped 52.47% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$346.9 million in 2022, then slipped by 7.04% to -$371.4 million in 2023, then soared by 52.47% to -$176.5 million in 2024, then tumbled by 79.59% to -$317.0 million in 2025, then rose by 11.74% to -$279.8 million in 2026.
• Per Business Quant, the three latest AMLX Enterprise Value figures stand at -$279.8 million (Q1 2026), -$317.0 million (Q4 2025), and -$344.0 million (Q3 2025).